

# ECLIPSE®

## Vena Cava Filter

### MRI Safety

The ECLIPSE® Filter was determined to be MR-conditional based on testing that was conducted on the G2® X Filter. The ECLIPSE® Filter is an electropolished version of the G2® X Filter.


The G2® X Filter was determined to be MR-conditional according to the terminology specified in the American Society for Testing and Materials (ASTM) International, Designation: F2503-05. Standard Practice for Marking Medical Devices and Other Items for Safety in the Magnetic Resonance Environment. ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, Pennsylvania, 2005.

Non-clinical testing demonstrated that the G2® X Filter is MR Conditional. A patient with this implant can be scanned safely immediately after placement under the following conditions:

- Static magnetic field of 3-Tesla or less
- Spatial gradient magnetic field of 720-Gauss/cm or less
- Maximum MR system reported whole-body-averaged specific absorption rate (SAR) of 3-W/kg for 15 minutes of scanning

In non-clinical testing, the G2® X Filter produced a temperature rise of 0.8°C at a maximum MR system-reported whole body averaged specific absorption rate (SAR) of 3-W/kg for 15-minutes of MR scanning in a 3-Tesla MR system using a transmit/receive body coil (Excite, Software G3.0-052B, General Electric Healthcare, Milwaukee, WI).

MR image quality may be compromised if the area of interest is in the exact same area or relatively close to the position of the G2® X Filter. Therefore, optimization of MR imaging parameters to compensate for the presence of this implant may be necessary.



---

## **ECLIPSE® Vena Cava Filter**

### **Indications for Use**

The ECLIPSE® Filter is indicated for use in the prevention of recurrent pulmonary embolism via permanent placement in the vena cava in the following situations:

- Pulmonary thromboembolism when anticoagulants are contraindicated.
- Failure of anticoagulant therapy for thromboembolic disease.
- Emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced.
- Chronic, recurrent pulmonary embolism where anticoagulant therapy has failed or is contraindicated.

The ECLIPSE® Filter may be removed according to the instructions supplied in the Instructions For Use under the Section labeled: Optional Procedure for Filter Removal.

### **Contraindications for Use**

**CAUTION: If the IVC diameter exceeds 28 mm, the filter must not be inserted into the IVC.**

The ECLIPSE® Filter should not be implanted in:

- Pregnant patients when fluoroscopy may endanger the fetus. Risks and benefits should be assessed carefully.
- Patients with an IVC diameter larger than 28 mm.
- Patients with risk of septic embolism.

**Please consult product labels and package inserts for indications, contraindications, hazards, warnings, cautions and instructions for use.**

Bard, Eclipse, and G2 are trademarks and/or registered trademarks of C. R. Bard, Inc., or an affiliate. All other trademarks are the property of their respective owners.  
Copyright © 2012, C. R. Bard, Inc. All Rights Reserved.

G70368 Rev 0

**BARD** | PERIPHERAL VASCULAR

Bard Peripheral Vascular, Inc.  
1625 W. 3rd Street Tempe, AZ 85281 USA  
Tel: 1 480 894 9515 / 1 800 321 4254  
Fax: 1 480 966 7062 / 1 800 440 5376  
[www.bardpv.com](http://www.bardpv.com)